Driven by Leqembi, Biogen beats Q2 expectations, raises full-year outlook

Biogen raised its full-year 2024 outlook after releasing its Q2 earnings report Thursday, which showed sales of its Alzheimer’s drug Leqembi and several newly launched drugs were slightly better than expected.